There's a new player on the antibody-drug conjugate (ADC) scene. UK-based Pheon Therapeutics has entered stage right with $68 million in funding that will be used to fund development of a pipeline of ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
STM32Cube is an STMicroelectronics original initiative to ease developers' life by reducing efforts, time and cost. STM32Cube covers the overall STM32 products portfolio. It includes a comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback